Literature DB >> 14614049

Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.

Xiaolin Liu-Jarin1, Mark B Stoopler, Haralambos Raftopoulos, Mark Ginsburg, Lyall Gorenstein, Alain C Borczuk.   

Abstract

Chemotherapy or chemoradiation is often used in Stage IIIA non-small cell lung carcinoma before surgical resection (neoadjuvant therapy). In reviewing the histopathology of such tumors after resection, the recognition that the pathologic changes are related to prior therapy and the assessment of tumor regression are both of importance. To refine histologic parameters for tumor regression and describe patterns of tumor reaction to therapy, we identified 30 lobectomy or pneumonectomy specimens from 1996-2000 in which neoadjuvant therapy was received before surgical resection. Histologic patterns of treatment-induced tumor regression were analyzed semiquantitatively and included necrosis, fibrosis, mixed inflammatory infiltrate, foamy macrophages, and giant cells. To identify clinical and histologic parameters that correlate with treatment response, the 30 specimens were graded for tumor regression. No correlation was found between tumor regression and age, gender, or type of therapy (chemoradiation versus chemotherapy alone). Squamous cell carcinoma showed a significantly higher rate of response than adenocarcinoma (P =.04), with a significant number of adenocarcinomas in the nonresponder subgroup (P =.05). Tumor size reduction by radiologic assessment, when compared with histologic regression, did not reveal a statistically significant association. However, a positive correlation was found between extent of fibrosis and radiologic estimate of size reduction.

Entities:  

Mesh:

Year:  2003        PMID: 14614049     DOI: 10.1097/01.MP.0000096041.13859.AB

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Authors:  Jose Luis Perez-Gracia; Miguel F Sanmamed; Ignacio Melero
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  [Therapy-induced tumor regression and regression grading in lung cancer].

Authors:  K Junker
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

3.  Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus.

Authors:  Johannes L Blaauwgeers; Ingrid Kappers; Houke M Klomp; José S Belderbos; Lea M Dijksman; Egbert F Smit; Pieter E Postmus; Marinus A Paul; Jan W Oosterhuis; Koen J Hartemink; Cornelis G Vos; Jacobus A Burgers; Max Dahele; Erik C Phernambucq; Birgit I Witte; Erik Thunnissen
Journal:  Virchows Arch       Date:  2013-04-03       Impact factor: 4.064

4.  The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.

Authors:  Masaki Goto; Masahito Naito; Koichi Saruwatari; Kakeru Hisakane; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Shogo Nomura; Keiju Aokage; Tomoyuki Hishida; Junji Yoshida; Kohei Yokoi; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-17       Impact factor: 4.553

5.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Authors:  T R Cottrell; E D Thompson; P M Forde; J E Stein; A S Duffield; V Anagnostou; N Rekhtman; R A Anders; J D Cuda; P B Illei; E Gabrielson; F B Askin; N Niknafs; K N Smith; M J Velez; J L Sauter; J M Isbell; D R Jones; R J Battafarano; S C Yang; L Danilova; J D Wolchok; S L Topalian; V E Velculescu; D M Pardoll; J R Brahmer; M D Hellmann; J E Chaft; A Cimino-Mathews; J M Taube
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

Review 6.  Foam Cells: One Size Doesn't Fit All.

Authors:  Valentina Guerrini; Maria Laura Gennaro
Journal:  Trends Immunol       Date:  2019-11-12       Impact factor: 16.687

7.  Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.

Authors:  William N William; Apar Pataer; Neda Kalhor; Arlene M Correa; David C Rice; Ignacio I Wistuba; John Heymach; J Jack Lee; Edward S Kim; Reginald Munden; Kathryn A Gold; Vassiliki Papadimitrakopoulou; Stephen G Swisher; Jeremy J Erasmus
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

8.  A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.

Authors:  Tina Cascone; Boris Sepesi; Heather Y Lin; Neda Kalhor; Edwin R Parra; Mei Jiang; Myrna C B Godoy; Jianjun Zhang; Frank V Fossella; Anne S Tsao; Vincent K Lam; Charles Lu; Frank E Mott; George R Simon; Mara B Antonoff; Reza J Mehran; David C Rice; Carmen Behrens; Annikka Weissferdt; Cesar Moran; Ara A Vaporciyan; J Jack Lee; Stephen G Swisher; Don L Gibbons; Ignacio I Wistuba; William N William; John V Heymach
Journal:  Clin Cancer Res       Date:  2020-03-19       Impact factor: 12.531

9.  Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy.

Authors:  Jun Zhao; Mark Z Ma; Hening Ren; Zhenqiu Liu; Martin J Edelman; Hong Pan; Li Mao
Journal:  Clin Cancer Res       Date:  2013-05-21       Impact factor: 12.531

10.  Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT.

Authors:  P-G Qiao; H-T Zhang; J Zhou; M Li; J-L Ma; N Tian; X-D Xing; G-J Li
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.